tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

RYTM Stock Latest News

Rhythm Pharmaceuticals says balance of deposits with SVB about $3.4M
The FlyRhythm Pharmaceuticals says balance of deposits with SVB about $3.4M
17d ago
RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Press ReleasesRhythm Pharmaceuticals Announces New Employment Inducement Grants
20d ago
RYTM
Rhythm Pharmaceuticals price target raised to $56 from $52 at Canaccord
The FlyRhythm Pharmaceuticals price target raised to $56 from $52 at Canaccord
25d ago
RYTM
Rhythm Pharmaceuticals announces key upcoming milestones
The FlyRhythm Pharmaceuticals announces key upcoming milestones
26d ago
RYTM
Rhythm Pharmaceuticals reports Q4 EPS (75c), consensus (81c)
The FlyRhythm Pharmaceuticals reports Q4 EPS (75c), consensus (81c)
26d ago
RYTM
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
Press ReleasesRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
26d ago
RYTM
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
Press ReleasesRhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
28d ago
RYTM
Rhythm Pharmaceuticals acquires Xinvento for upfront payment of $5M
The FlyRhythm Pharmaceuticals acquires Xinvento for upfront payment of $5M
28d ago
RYTM
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023
Press ReleasesRhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023
1M ago
RYTM
Rhythm Pharmaceuticals announces employment inducement grants
The FlyRhythm Pharmaceuticals announces employment inducement grants
2M ago
RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Press ReleasesRhythm Pharmaceuticals Announces New Employment Inducement Grants
2M ago
RYTM
Canaccord loves these biotech stocks — and gives them upside of more than 80%
Stock Analysis & IdeasCanaccord loves these biotech stocks — and gives them upside of more than 80%
2M ago
RARE
RYTM
Rhythm Pharmaceuticals announces HRQOL improvement from Phase 3 trial in BBS
The FlyRhythm Pharmaceuticals announces HRQOL improvement from Phase 3 trial in BBS
2M ago
RYTM
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome
Press ReleasesRhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome
2M ago
RYTM
Rhythm Pharmaceuticals assumed with a Buy at Canaccord
The FlyRhythm Pharmaceuticals assumed with a Buy at Canaccord
2M ago
RYTM
Amarin appoints Stewart to board of directors
The FlyAmarin appoints Stewart to board of directors
3M ago
AMRN
RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Press ReleasesRhythm Pharmaceuticals Announces New Employment Inducement Grants
3M ago
RYTM
Sell these stocks now, proven algorithm says
The FlySell these stocks now, proven algorithm says
4M ago
GH
KMX
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Press ReleasesRhythm Pharmaceuticals Announces New Employment Inducement Grants
4M ago
RYTM
Rhythm Pharmaceuticals Announces ▼IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
Press ReleasesRhythm Pharmaceuticals Announces ▼IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
4M ago
RYTM
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology
Press ReleasesRhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology
5M ago
RYTM
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
Press ReleasesRhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
5M ago
RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Press ReleasesRhythm Pharmaceuticals Announces New Employment Inducement Grants
5M ago
RYTM
Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek®
Press ReleasesRhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek®
5M ago
RYTM
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023
Press ReleasesRhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023
5M ago
RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Press ReleasesRhythm Pharmaceuticals Announces New Employment Inducement Grants
6M ago
RYTM
Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development
Press ReleasesRhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development
6M ago
RYTM
Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)
Press ReleasesRhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)
6M ago
RYTM
Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering
Press ReleasesRhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering
6M ago
RYTM
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.